• For Patients: Clinical Trials
  • Publications
  • Careers
  • Contact Us
INOVIO Pharmaceuticals
  • About INOVIO
    • Purpose, Mission and Values
    • Leadership
    • Partnerships
  • DNA Medicines Technology
    • Optimized Plasmid Design and Delivery
    • DNA Medicines Explained
    • The Promise of DNA Medicine
    • NEXT GEN DNA MEDICINE
  • DNA Medicines Pipeline
  • Investors & Media
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • FAQ
  • For Patients: Clinical Trials
  • Publications
  • Careers
  • Contact Us
INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

  • About INOVIO
    • Purpose, Mission and Values
    • Leadership
    • Partnerships
  • DNA Medicines Technology
    • Optimized Plasmid Design and Delivery
    • DNA Medicines Explained
    • The Promise of DNA Medicine
    • NEXT GEN DNA MEDICINE
  • DNA Medicines Pipeline
  • Investors & Media
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • FAQ
  • For Patients: Clinical Trials
  • Publications
  • Careers
  • Contact Us

Press Releases

INOVIO to Present at Upcoming Scientific Conferences

Posted on April 9, 2025

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Posted on March 18, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Posted on March 13, 2025

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Posted on March 12, 2025

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Posted on February 12, 2025

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Posted on February 10, 2025

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Posted on January 29, 2025

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Posted on January 9, 2025

INOVIO Announces Pricing of $30 Million Public Offering

Posted on December 13, 2024

INOVIO Announces Proposed Public Offering

Posted on December 12, 2024
Page 4 of 17« First«...23456...10...»Last »

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

INOVIO Pharmaceuticals
  • About Inovio
  • DNA Medicines Technology
  • DNA Medicines Pipeline
  • Investors & Media
  • For Patients
  • Publications
  • Careers
  • Contact Us
  • Safe Harbor Statement
  • Expanded Access
  • Privacy Policy
  • Terms & Conditions

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.